|
 The British drugmaker said on Tuesday that the treatment - Farxiga -
which is used for the most common form of diabetes, helped to
improve renal function or reduced the risk of death compared with a
placebo in diabetic and non-diabetic patients in a study.
Diabetes is known to have knock-on effects for the heart and
kidneys, prompting many drugmakers to test their diabetes treatments
on conditions affecting these organs.
Farxiga is part of the SGLT2-inhibitor class of antidiabetics which
also includes Eli Lilly and Boehringer Ingelheim's Jardiance and
Johnson & Johnson's Invokana.
Earlier this year, the U.S. Food and Drug Administration put
Jardiance up for a speedy review for a similar setting, but the drug
has yet to receive approval. Farxiga was granted this status by the
FDA last year.
Chronic kidney disease (CKD) is a serious, progressive condition
which affects nearly 700 million people worldwide, and has limited
treatment options.
[to top of second column] |
The positive data from AstraZeneca's late-stage DAPA-CKD trial also comes nearly
three months after U.S. regulators approved Farxiga as a medicine for heart
failure in certain patients, regardless of their diabetes status.
Farxiga had sales of $1.54 billion in 2019, making it among AstaZeneca's top
five treatments in terms of revenue.
The AstraZeneca trial also met all of its secondary goals, the company said.
Its shares were up 0.5% to 8,690 pence at 0850 GMT.
(Reporting by Aakash Jagadeesh Babu and Pushkala Aripaka in Bengaluru. Editing
by Bernard Orr and Jane Merriman)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
